目的 建立高效液相色谱(HPLC)测定左炔诺孕酮微球中的有关物质。方法 采用Waters Symmetry Shield RP8 (4.6 mm×250 mm,5 μm)色谱柱;以甲醇-乙腈-水(体积比100∶266∶500)为流动相,等度洗脱,流速1.2 mL·min-1;柱温40 ℃;检测波长220 nm;进样量50 μL。结果 左炔诺孕酮峰与相邻杂质峰及各相邻杂质峰之间均能达到良好的分离,微球辅料对有关物质测定无影响;左炔诺孕酮的定量限为2.73 ng,检测限为1.4 ng;在0.075 44～9.053 μg·mL-1范围内,相关系数为1.000 0(n=8);重复性实验测定杂质总量的相对标准偏差(RSD)为 7.5%(n=6)。结论 本方法专属性强,灵敏度高,可用于左炔诺孕酮微球的质量控制。
Abstract
OBJECTIVE To establish an isocratic elution method for determination of related substances of levonorgestrel microspheres. METHODS A C8 column (Waters Symmetry Shield RP8 4.6 mm×250 mm, 5 μm) was used. The mobile phase consisted of methanol-acetonitrile-water (100∶266∶500) and was eluted at the flow rate of 1.2 mL·min-1 and the column temperature was maintained at 40 ℃. The detection wavelength was set at 220 nm and the sample volume was 50 μL. RESULTS Levonorgestrel, near peaks and other impurities were well separated from each other. All excipients of levonorgestrel microspheres did not influence the determination of related substance. The LOQ and LOD of levonorgestrel were 2.73 ng and 1.4 ng, respectively. The linearity of levonorgestrel ranged from 0.075 44 to 9.053 μg·mL-1 with a correlation coefficient of 1.000 0(n=8). The repeatability RSD of total related substances (n=6)was 7.5%. CONCLUSION The proposed method shows high specify, accuracy and sensibility. It can be used for the quality control of levonorgestrel microspheres.
关键词
左炔诺孕酮 /
微球 /
高效液相色谱法 /
杂质测定
{{custom_keyword}} /
Key words
levonorgestrel /
microsphere /
HPLC /
impurity determination
{{custom_keyword}} /
中图分类号：
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] FENG S S, WANG W X, ZHENG C H. Decoration and application of PLGA microspheres [J]. Chin J Mod Appl Pharm(中国现代应用药学), 2016, 33(6):830-836.
[2] WANGF,TU J S,ZHANG J S, et al. Study on initial burst releasein PLGA microspheres controlled delivery systems[J]. Prog Pharm Sci(药学进展), 2003, 27(3):142-146.
[3] WANG L, CHEN W D. Determination of gefitinib PLGA Microsphere by RP-HPLC[J]. Cent South Pharm(中南药学), 2013, 11(7):547-548.
[4] DING Y F, FENG X J, TAO Y F, et al. Determination of content and entrapment efficiency of tyroserlenutide by HPLC[J]. Chin J Hosp Pharm(中国医院药学杂志), 2008, 28(7):583-585.
[5] WANG Z R, LIU B, YANG H. Studies on sustained release microspheres of levonorgestrol-poly 3-hydroxybutyrate[J]. Acta Pharm Sin(药学学报), 1999, 34(1):54-56.
[6] WANG S H, HAN J W, LING F, et al. Study on pharmaceutics of microspheres containing levonorgestrel and surface characteristics[J]. Chin J Pharm(中国医药工业杂志), 1994, 25(3):109-111.
[7] ZHENG Z, ZHANG Q, NING M Y. The methodology study on detection of the related substance in compound levonorgestrel vaginal ring[J]. Chin J Fam Plan(中国计划生育学杂志).2017, 25(5):297-303.
[8] SUN C Y, ZHAO Y P, ZHANG L, et al. Establishment of the international pharmacopoeia standard for norethisterone tablets[J]. Chin Pharm J(中国药学杂志), 2017, 52(2):147-151.
[9] Ch.P 2020. Vol Ⅳ(中国药典2020年版四部)[S]. 2020:180-181.
[10] BP 2022(英国药典2022版)[S]. 2022:837-839.
[11] EP 10.0(欧洲药典10.0版)[S]. 2020:2899-2902.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1024 KB)
